

Supplemental Material

Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials

Matthew A. Brown,^{1,2*} Martin Rudwaleit,^{3*} Floris A. van Gaalen,⁴ Nigil Haroon,⁵ Lianne S. Gensler,⁶ Carmen Fleurinck,⁷ Alexander Marten,⁸ Ute Massow,⁸ Natasha de Peyrecave,⁷ Thomas Vaux,⁹ Katy White,⁹ Atul Deodhar,¹⁰ Irene E. van der Horst-Bruinsma¹¹


*MAB and MR are joint first authors and contributed equally.

¹Genomics England, London, UK; ²Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, UK; ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany; ⁴Leiden University Medical Center, Department of Rheumatology, Leiden, The Netherlands; ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, Ontario, Canada; ⁶University of California, San Francisco, Department of Medicine/Rheumatology, San Francisco, California, USA; ⁷UCB Pharma, Brussels, Belgium; ⁸UCB Pharma, Monheim am Rhein, Germany; ⁹UCB Pharma, Slough, UK; ¹⁰Oregon Health & Science University, Division of Arthritis & Rheumatic Diseases, Portland, Oregon, USA; ¹¹Radboud University Medical Centre, Department of Rheumatology, Nijmegen, The Netherlands

Correspondence to: Matthew A. Brown (Genomics England, London, UK; matt.brown@genomicsengland.co.uk)

Supplemental Material

- 1
- SUPPLEMENTARY DATA**
- 2
- Figure S1. Pooling of data from the phase 3 BE MOBILE 1 and 2 and phase**
- 3
- 2 BE AGILE trials**



- 5
- ^aTrial ongoing. BKZ: bimekizumab; DBTP: double-blind treatment period; nr-axSpA: non-radiographic
- 6
- axial spondyloarthritis; OLE: open-label extension; PYs: patient-years; Q4W: every four weeks; r-axSpA:
- 7
- radiographic axial spondyloarthritis.